HomePodcastsThe Long Run with Luke TimmermanEp209: Mathai Mammen on Developing Drugs Against Undruggable TargetsThe Long Run with Luke TimmermanEp209: Mathai Mammen on Developing Drugs Against Undruggable TargetsSeptember 9, 2026 · 1 h 36 minPlay episodeShare from this pointShow notesMathai Mammen, CEO of Cambridge, Mass.-based Parabilis Medicine, on developing alpha helical peptide molecules against hard targets of disease.All episodes of The Long Run with Luke Timmerman